Induction of dormancy in hypoxic human papillomavirus-positive cancer cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 6, 2017, Pages E990-E998

  Hoppe Seyler, Karin ^a   Bossler, Felicitas ^a   Lohrey, Claudia ^a   Bulkescher, Julia ^a   Rösl, Frank ^a   Jansen, Lars ^b   Mayer, Arnulf ^c   Vaupel, Peter ^c   Dürst, Matthias ^b   Hoppe Seyler, Felix ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Cervical cancer; Human papillomavirus; Hypoxia; Mtor; Tumor virus

Indexed keywords

CARBONATE DEHYDRATASE IX; DOXORUBICIN; INITIATION FACTOR 4E BINDING PROTEIN 1; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN E6; PROTEIN E7; PROTEIN P53; PROTEIN S6; S6 KINASE; VIRUS ANTIGEN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CARBOHYDRATE METABOLISM; CELL AGING; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; DORMANCY; DOWN REGULATION; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IN VITRO STUDY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REOXYGENATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR ESCAPE; WART VIRUS; CELL LINE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; HELA CELL LINE; HEP-G2 CELL LINE; HOST PATHOGEN INTERACTION; HYPOXIA; MCF-7 CELL LINE; METABOLISM; NEOPLASM; PAPILLOMAVIRIDAE; PHYSIOLOGY; TUMOR CELL LINE; UTERINE CERVIX TUMOR; VIROLOGY;

CELL HYPOXIA; CELL LINE; CELL LINE, TUMOR; CELLULAR SENESCENCE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HCT116 CELLS; HELA CELLS; HEP G2 CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; HYPOXIA; MCF-7 CELLS; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 85011695882     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1615758114     Document Type: Article

References (61)

1. zur Hausen H (2002) Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2(5):342-350.
2. Howley PM, Schiller JT, Lowy DR (2013) Papillomaviruses. Fields Virology, eds Knipe DM, Howley PM (Lippincott, Williams & Wilkins, Philadelphia), 6th Ed, pp 1662-1703.
3. American Cancer Society (2015) Cancer Facts and Figures 2015 (American Cancer Society, Atlanta, GA).
4. Goodwin EC, et al. (2000) Rapid induction of senescence in human cervical carcinoma cells. Proc Natl Acad Sci USA 97(20):10978-10983.
5. Honegger A, et al. (2015) Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells. PLoS Pathog 11(3):e1004712.
6. Wells SI, et al. (2000) Papillomavirus E2 induces senescence in HPV-positive cells via pRB-And p21(CIP)-dependent pathways. EMBO J 19(21):5762-5771.
7. Campisi J (2013) Aging, cellular senescence, and cancer. Annu Rev Physiol 75:685-705.
8. Hellner K, Münger K (2011) Human papillomaviruses as therapeutic targets in human cancer. J Clin Oncol 29(13):1785-1794.
9. Hoppe-Seyler F, Hoppe-Seyler K (2011) Emerging topics in human tumor virology. Int J Cancer 129(6):1289-1299.
10. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP (2011) Pro-senescence therapy for cancer treatment. Nat Rev Cancer 11(7):503-511.
11. Acosta JC, Gil J (2012) Senescence: A new weapon for cancer therapy. Trends Cell Biol 22(4):211-219.
12. Nizard M, et al. (2013) Immunotherapy of HPV-Associated head and neck cancer: Critical parameters. OncoImmunology 2(6):e24534.
13. Stern PL, et al. (2012) Therapy of human papillomavirus-related disease. Vaccine 30(Suppl 5):F71-F82.
14. Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on human cancer. Nat Rev Cancer 8(12):967-975.
15. Höckel M, Vaupel P (2001) Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93(4):266-276.
16. Vaupel P, Mayer A (2007) Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev 26(2):225-239.
17. Vaupel P (2009) Pathophysiology of solid tumors. The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies, eds Molls M, Vaupel P, Nieder C, Anscher MS (Springer, Berlin, Heidelburg), pp 51-92.
18. Bachtiary B, et al. (2003) Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9(6):2234-2240.
19. Birner P, et al. (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60(17):4693-4696.
20. Sørensen BS, et al. (2013) Radiosensitivity and effect of hypoxia in HPV-positive head and neck cancer cells. Radiother Oncol 108(3):500-505.
21. Vaupel P, Höckel M, Mayer A (2007) Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 9(8):1221-1235.
22. Semenza GL (2014) Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol 9:47-71.
23. Chai TF, et al. (2011) Hypoxia-inducible factor independent down-regulation of thioredoxin- interacting protein in hypoxia. FEBS Lett 585(3):492-498.
24. Li Y, et al. (2013) HIF-And non-HIF-regulated hypoxic responses require the estrogenrelated receptor in Drosophila melanogaster. PLoS Genet 9(1):e1003230.
25. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63(6):1129-1136.
26. Vassilev LT, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659):844-848.
27. Leontieva OV, Blagosklonny MV (2012) Hypoxia and gerosuppression: The mTOR saga continues. Cell Cycle 11(21):3926-3931.
28. Leontieva OV, Demidenko ZN, Gudkov AV, Blagosklonny MV (2011) Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin. PLoS One 6(10):e26126.
29. Leontieva OV, et al. (2012) Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci USA 109(33):13314-13318.
30. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell type-specific repression of mRNA translation. Proc Natl Acad Sci USA 105(45):17414-17419.
31. Kang SA, et al. (2013) mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 341(6144):1236566.
32. Wouters BG, Koritzinsky M (2008) Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8(11):851-864.
33. Brugarolas J, et al. (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18(23):2893-2904.
34. Reiling JH, Hafen E (2004) The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev 18(23):2879-2892.
35. Ewald JA, Desotelle JA, Wilding G, Jarrard DF (2010) Therapy-induced senescence in cancer. J Natl Cancer Inst 102(20):1536-1546.
36. Olive PL, et al. (2001) Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61(24):8924-8929.
37. Seiwert TY, Salama JK, Vokes EE (2007) The concurrent chemoradiation paradigm- general principles. Nat Clin Pract Oncol 4(2):86-100.
38. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407(6801):249-257.
39. Noman MZ, et al. (2015) Hypoxia: A key player in antitumor immune response. Am J Physiol Cell Physiol 309(9):C569-C579.
40. Skeate JG, Woodham AW, Einstein MH, Da Silva DM, Kast WM (2016) Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother 12(6):1418-1429.
41. Molinolo AA, et al. (2012) mTOR as a molecular target in HPV-Associated oral and cervical squamous carcinomas. Clin Cancer Res 18(9):2558-2568.
42. Coppock JD, et al. (2013) Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition. Neoplasia 15(6):620-630.
43. Grabiner BC, et al. (2014) A diverse array of cancer-Associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov 4(5):554-563.
44. Fruman DA, Rommel C (2014) PI3K and cancer: Lessons, challenges and opportunities. Nat Rev Drug Discov 13(2):140-156.
45. Chiarini F, Evangelisti C, McCubrey JA, Martelli AM (2015) Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci 36(2):124-135.
46. Lim HJ, Crowe P, Yang JL (2015) Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol 141(4):671-689.
47. Leontieva OV, Blagosklonny MV (2010) DNA-damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-Activation of mTOR is associated with conversion to senescence. Aging (Albany NY) 2(12):924-935.
48. Herranz N, et al. (2015) mTOR regulates MAPKAPK2 translation to control the senescence-Associated secretory phenotype. Nat Cell Biol 17(9):1205-1217.
49. Laberge RM, et al. (2015) MTOR regulates the pro-Tumorigenic senescence-Associated secretory phenotype by promoting IL1A translation. Nat Cell Biol 17(8):1049-1061.
50. Guba M, et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. NatMed 8(2):128-135.
51. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M (2001) Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA 98(3):1218-1223.
52. Koumenis C, et al. (2001) Regulation of p53 by hypoxia: Dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21(4):1297-1310.
53. Achison M, Hupp TR (2003) Hypoxia attenuates the p53 response to cellular damage. Oncogene 22(22):3431-3440.
54. Meugnier E, Rome S, Vidal H (2007) Regulation of gene expression by glucose. Curr Opin Clin Nutr Metab Care 10(4):518-522.
55. Havula E, Hietakangas V (2012) Glucose sensing by ChREBP/MondoA-Mlx transcription factors. Semin Cell Dev Biol 23(6):640-647.
56. Leitz J, et al. (2014) Oncogenic human papillomaviruses activate the tumor-Associated lens epithelial-derived growth factor (LEDGF) gene. PLoS Pathog 10(3):e1003957.
57. Korotchkina LG, et al. (2010) The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) 2(6):344-352.
58. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402-408.
59. Schmitz M, et al. (2012) Loss of gene function as a consequence of human papillomavirus DNA integration. Int J Cancer 131(5):E593-E602.
60. Tóth ZE, Mezey E (2007) Simultaneous visualization of multiple antigens with tyramide signal amplification using antibodies from the same species. J Histochem Cytochem 55(6):545-554.
61. Hopman AH, Ramaekers FC, Speel EJ (1998) Rapid synthesis of biotin-, digoxigenin-, trinitrophenyl-, and fluorochrome-labeled tyramides and their application for In situ hybridization using CARD amplification. J Histochem Cytochem 46(6):771-777.